<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20261023071529N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-20</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effects of two methods transcutaneous electrical nerve stimulation and progressive muscle relaxation on fatigue in stroke patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects of two methods transcutaneous electrical nerve stimulation and progressive muscle relaxation on fatigue in stroke patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-12-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>117</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/94412</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Patients will be assigned to three groups TENS, Progressive Muscle Relaxation (PMR), and a control group, using a block randomization method with block sizes of three and six, facilitated by the online system "Sealed Envelope." Following the generation of the randomization sequence, assignments will be designated by codes A, B, and C, and placed into opaque, sealed, and numbered envelopes. As each eligible patient enters the study, the corresponding envelope (in numerical order) will be opened to reveal the assigned group. This process will continue until the required sample size is reached.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Stroke. Condition 2: Stroke. Condition 3: Stroke. Condition 4: Stroke.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The TENS intervention will be administered by the researcher using a Berjis ST90 device. It will involve bilateral stimulation of the common peroneal nerve at a frequency of 100 Hz and a pulse width of 200 microseconds. The intensity will be set to a tolerable sensory level—below the motor threshold—and the intervention will be applied daily for 30 to 45 minutes over 5 consecutive days. Intervention 2: Intervention group: The progressive muscle relaxation intervention, based on the Jacobson method, will be conducted daily for 30 to 45 minutes over 5 consecutive days, following instruction by the researcher and the use of an educational video. The exercises will be performed in a lying position, proceeding from head to toe; this involves contracting the muscles for 5 to 10 seconds, followed by a 5-second release, all under the supervision and guidance of the researcher. Intervention 3: Control group:This group will not receive a placebo and will instead receive only the standard care provided in the ward, in accordance with hospital protocol. Such care encompasses routine nursing interventions, pharmacological treatment as prescribed by the attending physician, physiotherapy (if ordered), and other standard care typically provided to patients hospitalized during the acute phase of a stroke. No interventions such as Transcutaneous Electrical Nerve Stimulation (TENS) or Progressive Muscle Relaxation (PMR) will be administered to this group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Given that the plan for releasing and sharing the de-identified individual data of participants has not yet been finalized, the decision regarding this matter is deferred to subsequent stages of the research.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Matina Rajaee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Dr.Kharazmi Educational Complex, University Campus, Eastern Entrance of Ferdowsi University of Mashhad, Azadi Square, Mashhad, Iran</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>+98 902 960 6617</telephone>
        <email>rajaeim4042@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>tayebe pourghaznein</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Dr.Kharazmi Educational Complex, University Campus, Eastern Entrance of Ferdowsi University of Mashhad, Azadi Square, Mashhad, Iran</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>05131428000- 8728</telephone>
        <email>pourghazneint@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of ischemic stroke by a specialist physician(CT or MRI)
Full level of consciousness (GCS=15)
MRS score less than or equal to 2
Being between the third and seventh day of hospitalization
Ages 30 to 75
Stability of vital signs
Informed consent for participation in the study
Sufficient visual, auditory, cognitive ability to respond questions.
Absence of paralysis of the limbs
Access to a mobile phone for online training and questionnaires
Ability to read and write
Absence of severe and unstable physical or psychiatric illnesses
Absence of implanted electronic devices
Absence of skin lesions at the electrode placement sites
Not taking antidepressants or sedatives
Lack of sensitivity to adhesive or nickel
Absence of pregnancy
Absence of epilepsy</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Suffering from severe and unstable physical or psychiatric illnesses
Use of antidepressant or sedative medications
Presence of implanted electronic devices
Skin lesions at the electrode placement sites
History of epilepsy
Use of similar complementary treatments
Allergy to electrode adhesives or nickel</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I60</hc_code>
      <hc_code>I61</hc_code>
      <hc_code>I62</hc_code>
      <hc_code>I63</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Nontraumatic subarachnoid hemorrhage</hc_keyword>
      <hc_keyword>Nontraumatic intracerebral hemorrhage</hc_keyword>
      <hc_keyword>Other and unspecified nontraumatic intracranial hemorrhage</hc_keyword>
      <hc_keyword>Cerebral infarction</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The TENS intervention will be administered by the researcher using a Berjis ST90 device. It will involve bilateral stimulation of the common peroneal nerve at a frequency of 100 Hz and a pulse width of 200 microseconds. The intensity will be set to a tolerable sensory level—below the motor threshold—and the intervention will be applied daily for 30 to 45 minutes over 5 consecutive days.</i_keyword>
      <i_keyword>Intervention group: The progressive muscle relaxation intervention, based on the Jacobson method, will be conducted daily for 30 to 45 minutes over 5 consecutive days, following instruction by the researcher and the use of an educational video. The exercises will be performed in a lying position, proceeding from head to toe; this involves contracting the muscles for 5 to 10 seconds, followed by a 5-second release, all under the supervision and guidance of the researcher.</i_keyword>
      <i_keyword>Control group:This group will not receive a placebo and will instead receive only the standard care provided in the ward, in accordance with hospital protocol. Such care encompasses routine nursing interventions, pharmacological treatment as prescribed by the attending physician, physiotherapy (if ordered), and other standard care typically provided to patients hospitalized during the acute phase of a stroke. No interventions such as Transcutaneous Electrical Nerve Stimulation (TENS) or Progressive Muscle Relaxation (PMR) will be administered to this group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fatigue Score. Timepoint: Measurement of fatigue at the beginning (before the intervention) and at the end of the intervention (after the final intervention session). Method of measurement: Multidimensional Fatigue Inventory (MFI).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Degree of disability or dependence in activities of daily living among individuals who have suffered a stroke. Timepoint: Measurement at the beginning (pre-intervention) and at the end of the intervention (after the final intervention session). Method of measurement: (Modified Rankin Scale - MRS).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-10-06</approval_date>
        <contact_name>Research Ethics Committees of School of Nursing &amp; Midwifery - Mashhad university Of Medical Sciences</contact_name>
        <contact_address>School of Nursing and Midwifery, Shahid Dr.Kharazmi Educational Complex, Medical Sciences Campus, Eastern Entrance of Ferdowsi University, Azadi Square, Mashhad, Iran Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
